Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1-2
|
| pubmed:dateCreated |
1992-7-23
|
| pubmed:abstractText |
IVIG is the definitive therapy for primary immunodeficiency diseases associated with hypogammaglobulinemia or specific antibody deficiencies. Administration of IVIG is relatively safe, but occasional adverse reactions are usually self-limited and generally are not an indication for stopping therapy. Home administration of IVIG has found increasing favor among treating physicians and their patients.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0731-8235
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
10
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1-12
|
| pubmed:dateRevised |
2005-11-16
|
| pubmed:meshHeading |
pubmed-meshheading:1606517-Agammaglobulinemia,
pubmed-meshheading:1606517-Female,
pubmed-meshheading:1606517-Humans,
pubmed-meshheading:1606517-IgA Deficiency,
pubmed-meshheading:1606517-Immunoglobulins, Intravenous,
pubmed-meshheading:1606517-Immunologic Deficiency Syndromes,
pubmed-meshheading:1606517-Infant,
pubmed-meshheading:1606517-Male
|
| pubmed:articleTitle |
Clinical use of immune serum globulin as replacement therapy in patients with primary immunodeficiency syndromes.
|
| pubmed:affiliation |
Department of Pediatrics, University of Michigan, Ann Arbor 48109-2029.
|
| pubmed:publicationType |
Journal Article,
Review
|